Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 8, Issue 5, 2011, Pages 340-345

  Beeh, Kai Michael ^a   Wagner, Frank ^b   Khindri, Sanjeev ^c   Drollmann, Anton Franz ^d  

^a Institut fur Atemwegsforschung INSAF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bronchodilator; COPD; Dyspnoea; FEV 1; Indacaterol; Inspiratory capacity

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; INDACATEROL; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DYSPNEA; ENDURANCE; ERGOMETRY; EXERCISE; EXPIRATORY RESERVE VOLUME; FEMALE; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; MALE; MEDICAL HISTORY; MONOTHERAPY; MULTICENTER STUDY; PATIENT MONITORING; PLETHYSMOGRAPHY; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; ST SEGMENT DEPRESSION; TREATMENT DURATION; WORKLOAD;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSPNEA; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; INSPIRATORY CAPACITY; LINEAR MODELS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TREATMENT OUTCOME;

EID: 80053058889     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.594464     Document Type: Article

References (22)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD (updated 2009). Available at: http://www.goldcopd.com/(accessed 14 Jan 2010).
2. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775-783. (Pubitemid 41030946)
3. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B. Efcacy and safety of indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10:11.
4. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, on behalf of the INVOLVE (indacaterol: value in COPD pulmonary disease: longer term validation of efcacy and safety) study investigators. Ef-cacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Torax 2010; 65:473-479.
5. Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S. Bronchodilator efects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ter 2009; 22:492-496.
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO workshop report. Bethseda, National Heart, Lung, and Blood Institute. April 2001(updated 2005). Available at www.gold.copd.com (accessed 14 Jan 2010).
7. Roca J, Whipp BJ, Agusti AGN, Anderson SD, Casaburi R, Cotes JE, Donner CF, Estenne M, Folgering H, Higenbottam TW
8. Killian KJ, Palange P, Patessio A, Prefaut C, Sergysels R, Wagner PD, Weisman I. Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. European Respiratory Society. Eur Respir J 1997; 10:2662-2689. (Pubitemid 28048650)
9. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguila-niu B, Make B, Magnussen H. Efects of tiotropium on lung hyper-infation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832-840. (Pubitemid 38807355)
10. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. Te measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751-758. (Pubitemid 14121920)
11. Witek TJ, Jr., Mahler DA. Meaningful efect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56:248-255. (Pubitemid 36513486)
12. Witek TJ, Jr., Mahler DA. Minimal important diference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21:267-272. (Pubitemid 36204541)
13. Borg GAV. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381.
14. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J 2005; 26:153-161. (Pubitemid 40945944)
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Ped-ersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry, Eur Respir J 2005,26;319-338. (Pubitemid 41079078)
16. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. Standardisation of the measurement of lung volumes Eur Respir J 2005; 26: 511-522. (Pubitemid 41264217)
17. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, Lisboa C. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory fow limitation at rest. Eur Respir J 2000; 16:269-275. (Pubitemid 30627482)
18. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinfation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:967-975. (Pubitemid 26081647)
19. O'Donnell DE, Lam M, Webb KA. Measurements of symptoms, lung hyperinfation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1557-1565.
20. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K. Efect of futicasone propionate/salmeterol on lung hyperinfation and exercise endurance in COPD. Chest 2006; 130:647-656. (Pubitemid 44423592)
21. Mahler DA, Witek TJ Jr. Te MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2:99-103. (Pubitemid 40776229)
22. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102:1033-1044.